XSWXCOPN
Market cap1.07bUSD
Dec 20, Last price
59.70CHF
1D
1.02%
1Q
-22.97%
Jan 2017
-64.74%
IPO
-65.69%
Name
Cosmo Pharmaceuticals NV
Chart & Performance
Profile
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 92,780 -9.12% | 102,089 56.88% | 65,074 6.77% | |||||||
Cost of revenue | 63,554 | 37,837 | 29,305 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 29,226 | 64,252 | 35,769 | |||||||
NOPBT Margin | 31.50% | 62.94% | 54.97% | |||||||
Operating Taxes | 6,264 | 6,968 | 2,330 | |||||||
Tax Rate | 21.43% | 10.84% | 6.51% | |||||||
NOPAT | 22,962 | 57,284 | 33,439 | |||||||
Net income | (4,932) -128.63% | 17,225 -20.52% | 21,672 -374.29% | |||||||
Dividends | (16,890) | (15,607) | ||||||||
Dividend yield | 2.06% | 1.55% | ||||||||
Proceeds from repurchase of equity | (11,788) | (24,477) | (18,984) | |||||||
BB yield | 1.44% | 2.43% | 1.71% | |||||||
Debt | ||||||||||
Debt current | 897 | 171,827 | 889 | |||||||
Long-term debt | 2,222 | 3,739 | 171,667 | |||||||
Deferred revenue | 479 | |||||||||
Other long-term liabilities | 98,288 | 1,990 | 2,392 | |||||||
Net debt | (50,442) | (18,532) | (75,081) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 33,623 | 33,226 | 12,611 | |||||||
CAPEX | (3,347) | (7,310) | (8,504) | |||||||
Cash from investing activities | 42,303 | 1,689 | 24,857 | |||||||
Cash from financing activities | (211,266) | (46,133) | (27,247) | |||||||
FCF | 75,473 | 33,790 | 23,395 | |||||||
Balance | ||||||||||
Cash | 50,275 | 240,953 | 222,207 | |||||||
Long term investments | 3,286 | (46,855) | 25,430 | |||||||
Excess cash | 48,922 | 188,994 | 244,383 | |||||||
Stockholders' equity | 286,778 | 273,666 | 305,275 | |||||||
Invested Capital | 480,241 | 447,646 | 437,487 | |||||||
ROIC | 4.95% | 12.94% | 10.44% | |||||||
ROCE | 5.52% | 8.76% | 4.58% | |||||||
EV | ||||||||||
Common stock shares outstanding | 16,105 | 16,425 | 16,904 | |||||||
Price | 50.90 -16.83% | 61.20 -6.71% | 65.60 -22.82% | |||||||
Market cap | 819,751 -18.45% | 1,005,234 -9.35% | 1,108,906 -9.85% | |||||||
EV | 776,185 | 1,005,055 | 1,059,677 | |||||||
EBITDA | 43,487 | 78,108 | 43,138 | |||||||
EV/EBITDA | 17.85 | 12.87 | 24.56 | |||||||
Interest | 8,526 | 9,159 | 8,990 | |||||||
Interest/NOPBT | 29.17% | 14.25% | 25.13% |